Pharmaceutical Equivalence

Pharmaceutical Equivalence for the Global Pharmaceutical Industry

Customized methodologies for R&D and quality control, with global reach

Customized methodologies and global support

We develop customized methodologies to meet the specific needs of the pharmaceutical industry, whether for research and development or quality control.


We are strategic partners for international companies seeking to conduct pharmaceutical equivalence studies in Brazil, with consolidated expertise in antineoplastics and other high-complexity therapeutic classes.

Our services

Pharmaceutical Equivalence

Synvia is an ANVISA-accredited Pharmaceutical Equivalence Center, registered under No. 4667.


We conduct comprehensive Pharmaceutical Equivalence studies, covering physicochemical and microbiological assays, in full compliance with RDC No. 31/2010.


We perform assays across solid, semi-solid, and liquid dosage forms, including antineoplastic drugs and other high-criticality molecules.

Laboratório bioanalítico da Synvia integrado ao centro clínico para validação de métodos e estudos bioanalíticos
Laboratório bioanalítico da Synvia integrado ao centro clínico para validação de métodos e estudos bioanalíticos

Comparative Dissolution Profile

We conduct Comparative Dissolution Profile (CDP) studies for post-registration purposes, in full compliance with the requirements of RDC No. 73.


The CDP is required by ANVISA in various regulatory contexts, including changes in manufacturing site, raw material supplier, or production process.


It may also be a necessary step in the planning and conduct of bioequivalence studies.

Biowaivers

We cover the full scope of Biowaiver studies in accordance with RDC No. 749/2022.


The service applies to generic, similar, new, and innovative drugs, including post-registration situations.


Covering the majority of dosage forms provided for in current regulations, our team assesses the most appropriate biowaiver strategy for each project.

Laboratório bioanalítico da Synvia integrado ao centro clínico para validação de métodos e estudos bioanalíticos

Assays with Oncological Drugs

ANVISA-authorized laboratory for conducting pharmaceutical equivalence studies and other assays involving oncological drugs.


Analyses are conducted in dedicated areas, with specific biosafety procedures, a highly qualified team, and continuous monitoring.

Laboratório da Synvia realizando ensaios clínicos com medicamentos oncológicos em ambiente de biossegurança
Laboratório da Synvia realizando ensaios clínicos com medicamentos oncológicos em ambiente de biossegurança

The Largest Analytical Park in Latin America

Our modern facilities include state-of-the-art equipment, such as:

Parque analítico da Synvia com equipamentos de espectrometria de massas e LC-MS/MS para estudos bioanalíticos
Parque analítico da Synvia com equipamentos de espectrometria de massas e LC-MS/MS para estudos bioanalíticos
Parque analítico da Synvia com equipamentos de espectrometria de massas e LC-MS/MS para estudos bioanalíticos

+30 LC-MS/MS

+30 LC-MS/MS

+25 LC-DAD

+25 LC-DAD

GC-FID

GC-FID

GC-MS/MS

GC-MS/MS

ICP-MS

ICP-MS

ICP-OES

ICP-OES

LC-FL

LC-FL

UV-VIS

UV-VIS

Dissolution apparatus I, II, and III

Dissolution apparatus I, II, and III

Validated infrastructure compliant with global regulatory standards

Our facilities meet international quality and safety standards, ensuring the traceability and credibility of every result delivered.

ANVISA
ANVISA
ANVISA
EMA
EMA
EMA
FDA
FDA
FDA
GCC
GCC
GCC

Pharma Solutions

Integrated solutions for the pharmaceutical industry

From clinical research to laboratory analyses and regulatory studies, our Pharma solutions connect all the necessary steps for the development, validation, and registration of medications.

Contact

Talk to our experts

Discover how Synvia can support your pharmaceutical equivalence studies, dissolution profiles, and biowaiver strategies.

Contact

Talk to our experts

Discover how Synvia can support your pharmaceutical equivalence studies, dissolution profiles, and biowaiver strategies.